Grant: Operating Grant: Priority Announcement (IHSPR)
University of Calgary
$60,831.00
Transferring knowledge of amiodarone safety monitoring to the community practice setting using a formalized care pathway
EF 2008-09
Résumé
In the busy world of medicine, new information about treating diseases is often delayed in reaching the community doctor or overlooked completely. The field of knowledge translation seeks to find better ways to get that information to the doctor. We want to study the use of clinical guidance from a care pathway as a tool to help doctors know better how to treat people with amiodarone. This is the most effective medication available to reverse the irregular heart beat called atrial fibrillation. As the population ages, atrial fibrillation is becoming more common. While not immediately life threatening, many patients do find their daily life limited by decreased energy or difficulties breathing and others suffer debilitating strokes when atrial fibrillation is not adequately managed.
Unfortunately, in the past, a lack of understanding of how best to use amiodarone has lead to a reputation for excessive adverse effects. In large trials where amiodarone use is managed in the community, the reported rate of discontinuation is 15 to 20%. Ironically fear of potential adverse effects has made many physicians reluctant to use this agent and ensured they remain unknowledgeable about how to manage it. In contrast, patients managed systematically in our monitoring clinic have a < 2% rate of discontinuation, and 85% are successfully maintained in sinus rhythm.
The use of amiodarone continues to increase, but the knowledge of how to manage it has not reached the community. Its increased use without systematic monitoring is as dangerous as using blood thinners without regular testing, but because amiodarone works so slowly, bad effects can sneak up unnoticed many months after it is started.
Our study of how to best get information regarding drug management to community physicians will help us in two ways. First, it will provide a model for future efforts to improve the use of other drugs. Second, it should improve the management of amiodarone in our community.
Programme
Operating Grant: Priority Announcement (IHSPR)
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
179181
Name
Pollak P. T
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Clinical
Prcname2
Knowledge Translation & Exchange
Projecttitle
Transferring knowledge of amiodarone safety monitoring to the community practice setting using a formalized care pathway
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$60,831
Cihrequipment2
$0
Programname2
Operating Grant: Priority Announcement (IHSPR)
Keyworddelim
Amiodarone; Atrial Fibrillation; Care Pathway; Improved Monitoring; Knowledge Application
Abstract
In the busy world of medicine, new information about treating diseases is often delayed in reaching the community doctor or overlooked completely. The field of knowledge translation seeks to find better ways to get that information to the doctor. We want to study the use of clinical guidance from a care pathway as a tool to help doctors know better how to treat people with amiodarone. This is the most effective medication available to reverse the irregular heart beat called atrial fibrillation. As the population ages, atrial fibrillation is becoming more common. While not immediately life threatening, many patients do find their daily life limited by decreased energy or difficulties breathing and others suffer debilitating strokes when atrial fibrillation is not adequately managed.
Unfortunately, in the past, a lack of understanding of how best to use amiodarone has lead to a reputation for excessive adverse effects. In large trials where amiodarone use is managed in the community, the reported rate of discontinuation is 15 to 20%. Ironically fear of potential adverse effects has made many physicians reluctant to use this agent and ensured they remain unknowledgeable about how to manage it. In contrast, patients managed systematically in our monitoring clinic have a < 2% rate of discontinuation, and 85% are successfully maintained in sinus rhythm.
The use of amiodarone continues to increase, but the knowledge of how to manage it has not reached the community. Its increased use without systematic monitoring is as dangerous as using blood thinners without regular testing, but because amiodarone works so slowly, bad effects can sneak up unnoticed many months after it is started.
Our study of how to best get information regarding drug management to community physicians will help us in two ways. First, it will provide a model for future efforts to improve the use of other drugs. Second, it should improve the management of amiodarone in our community.
Competitiondate
200809
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pollak, P. T
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $60,831~ $0~